{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-139364","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.652060+00:00","generated_at":"2026-06-01T23:20:37.337318+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Spero Therapeutics Q1 net loss $12.7M; SPR720 Phase 2a data expected 2H 2024","bullets":["Net loss $12.7M ($0.24/share) vs $13.3M ($0.25/share) in Q1 2023; revenue $9.3M up from $2.1M.","Cash $82.3M at March 31, 2024, increased from $76.3M after receiving $23.8M milestone from GSK for tebipenem HBr.","SPR720 Phase 2a top-line data for NTM-PD expected 2H 2024; tebipenem HBr Phase 3 PIVOT-PO enrollment ongoing, completion 2H 2025.","SPR206 received FDA Fast Track designation for HABP/VABP due to CRABc and CRPA; Phase 2 contingent on non-dilutive funding.","Reaffirmed cash runway into late 2025 based on current operating plans."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-139364","json":"https://secwatch.observer/filing/0001193125-24-139364.json","markdown":"https://secwatch.observer/filing/0001193125-24-139364.md","text":"https://secwatch.observer/filing/0001193125-24-139364.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312524139364/0001193125-24-139364-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312524139364/d756109d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:20:37.337318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ed99c0dadf4d25c7829522f4d05579fb364dbb3","claim":"Spero Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $9.3 million, net income net loss of $12.7 million, or ($0.24) per share of common stock, basic and diluted, EPS ($0.24) per share.","evidence_excerpt":"net loss of $13.3 million, or ($0.25) per share of common stock, basic and diluted, for the first quarter ended March 31, 2023. • Total revenue for the first quarter of 2024 was $9.3 million, compared with total revenue of $2.1 million for the first quarter of 2023. The revenue increase for the first quarter of 2024 was primarily due to an increase in collaboration","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312524139364/0001193125-24-139364-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$9.3 million"},{"label":"Net income","value":"net loss of $12.7 million, or ($0.24) per share of common stock, basic and diluted"},{"label":"EPS","value":"($0.24) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}